Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, ...

Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended treatment benefit versus transarterial chemoembolization (TACE), according ...

There's a possible new standard of care on the horizon for unresectable hepatocellular carcinoma (HCC) after years of failed attempts to improve upon the outcomes of the current protocol — stand-alone ...

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial Patients with unresectable ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Please provide your email address to receive an email when new articles are posted on . Postprocedural imaging showed 10% of patients had new portal vein thrombosis after transarterial ...